Meeting
2020 ASCO Virtual Scientific Program
KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
Authors
Sundar Jagannath
Mount Sinai Medical Center, New York, NY
Sundar Jagannath , Yi Lin , Hartmut Goldschmidt , Donna Ellen Reece , Ajay K. Nooka , Paula Rodríguez Otero , Kosei Matsue , Nina Shah , Larry D. Anderson, Jr , Kimberly Wilson , Arlene S. Swern , Faiza Zafar , Amit Balkrishna Agarwal , David Samuel DiCapua Siegel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
tbd
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8525)
DOI
10.1200/JCO.2020.38.15_suppl.8525
Abstract #
8525
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
First Author: Larry D. Anderson, Jr
Poster
2023 ASCO Annual Meeting
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).
First Author: Nicholas Stong
Poster
2023 ASCO Annual Meeting
Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).
First Author: Dan T. Vogl
Poster
2023 ASCO Annual Meeting
Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).
First Author: Julia Piasecki